Provectus Receives counseling From FDA On tract to Approval for state of matter 3 Trial ... MarketWatch (press release) Its medicine drug PH-10 also targets abnormal or diseased cells, with the current focussing on psoriasis and atopic dermatitis. Provectus has lately completed Phase 2 trials of PV-10 as type A therapy for metastatic melanoma, and of PH-10 As a topical ... and more » Link To Article
No comments:
Post a Comment